$AIAI

AIAI Holdings Corp (AIAI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0002096362 0002096362 2026-07-31 2026-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

AIAI Holdings (NASDAQ:AIAI) said its portfolio company MediGuide launched a “Longevity Intelligence” service for personalized preventive healthcare. The offering combines advanced diagnostics, predictive health intelligence, physician-reviewed recommendations, and coordinated care. AIAI expects Transformational AI to help convert biomarker and clinical data into risk insights and care-pathway recommendations.

AIAI Holdings (NASDAQ:AIAI) said it deployed its “Bid Accelerator” AI application at wholly owned subsidiary C.C. Carlton Industries to streamline construction bid preparation. The company said it analyzed over $7 billion from 1,500 bids to build the tool and expects productivity and efficiency gains to contribute to financial performance in 1H 2027.

AIAI Holdings (NASDAQ:AIAI) said it deployed its “Bid Accelerator” AI application at wholly owned subsidiary C.C. Carlton Industries to streamline construction bid preparation. The company said it analyzed $7 billion from 1,500 bids to build it and expects productivity and efficiency gains to contribute to financial performance in 1H 2027.

AIAI Holdings (NASDAQ:AIAI) said its portfolio company MediGuide launched a precision healthcare solution combining AI-enabled diagnostic support, expert clinical review, and genetic, molecular, clinical, and lifestyle data. The offering builds on MediGuide’s medical second opinion services and targets earlier detection and more personalized treatment guidance, according to the company.

AIAI Holdings (NASDAQ:AIAI) said its portfolio company MediGuide launched a precision healthcare solution using AI-enabled diagnostic support plus genetic, molecular, clinical and lifestyle data with physician review. The company links the launch to its Medical Second Opinion services and cites growing insurer demand for evidence-based clinical review.

NetraMark Holdings Inc. (TSX: AIAI, OTCQB: AINMF) said it signed a new contract with a contract research organization partner to analyze phase 2 neurodegeneration trial data using its NetraAI explainable AI platform. The company said it is its first CRO-based contract and aims to identify model-derived subgroups and treatment-response patterns to support future trial planning.

Glajch Jeffrey sold 21,780 shares of AIAI Holdings Corp (AIAI) at an average of $13.38 ($12.97–$13.60, $0.29M total) across 2 trades over 2026-07-06 to 2026-07-07.

AIAI Holdings (NASDAQ:AIAI) said its portfolio company Constellation Network launched Gate AI, a security layer for AI apps that sits between applications and LLMs. Gate AI targets prompt injection protection, claims 20%+ token cost reduction via prompt compression, and provides verified auditability via a Digital Evidence API. The release cites benchmark results and mentions free and paid tiers.

AIAI Holdings (NASDAQ:AIAI) said its portfolio company Constellation Network launched Gate AI, a real-time security layer for AI apps. Gate AI is model-provider agnostic and claims prompt-injection protection, token compression of 20% or more, data leakage scanning, and blockchain-anchored auditability. It cites benchmark results (F1 97.4% at 1% false positives) and offers free and paid tiers.